[go: up one dir, main page]

HK1202813A1 - Progesterone receptor modulators for use in preventing or treating androgen mediated diseases - Google Patents

Progesterone receptor modulators for use in preventing or treating androgen mediated diseases Download PDF

Info

Publication number
HK1202813A1
HK1202813A1 HK15103497.5A HK15103497A HK1202813A1 HK 1202813 A1 HK1202813 A1 HK 1202813A1 HK 15103497 A HK15103497 A HK 15103497A HK 1202813 A1 HK1202813 A1 HK 1202813A1
Authority
HK
Hong Kong
Prior art keywords
progesterone receptor
mediated diseases
preventing
receptor modulators
treating androgen
Prior art date
Application number
HK15103497.5A
Other languages
English (en)
Chinese (zh)
Inventor
Oliver Pohl
Jean-Pierre Gotteland
Original Assignee
Preglem S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Preglem S.A. filed Critical Preglem S.A.
Publication of HK1202813A1 publication Critical patent/HK1202813A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15103497.5A 2012-05-16 2013-05-15 Progesterone receptor modulators for use in preventing or treating androgen mediated diseases HK1202813A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12168319.7A EP2664325A1 (fr) 2012-05-16 2012-05-16 Procédés de prévention ou de traitement des maladies induites par les androgènes
EP12168319.7 2012-05-16
PCT/IB2013/053959 WO2013171684A1 (fr) 2012-05-16 2013-05-15 Modulateurs des récepteurs à la progestérone pour leur utilisation dans la prévention ou le traitement des maladies médiées par les androgènes

Publications (1)

Publication Number Publication Date
HK1202813A1 true HK1202813A1 (en) 2015-10-09

Family

ID=48699889

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103497.5A HK1202813A1 (en) 2012-05-16 2013-05-15 Progesterone receptor modulators for use in preventing or treating androgen mediated diseases

Country Status (14)

Country Link
US (1) US20150209373A1 (fr)
EP (2) EP2664325A1 (fr)
JP (1) JP2015516461A (fr)
KR (1) KR20150013596A (fr)
CN (1) CN104411302A (fr)
AU (1) AU2013261081A1 (fr)
BR (1) BR112014028629A2 (fr)
CA (1) CA2872233A1 (fr)
CO (1) CO7151508A2 (fr)
EA (1) EA201491939A1 (fr)
HK (1) HK1202813A1 (fr)
MX (1) MX2014013911A (fr)
TW (1) TW201408306A (fr)
WO (1) WO2013171684A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11883675B2 (en) 2019-12-20 2024-01-30 Medtronic, Inc. Transcutaneous energy transfer system including alarm

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4039561A1 (de) * 1990-12-07 1992-07-09 Schering Ag Verwendung von antigestagenen zur herstellung von arzneimitteln
JP4260886B2 (ja) * 1996-05-01 2009-04-30 アメリカ合衆国 新規の抗プロゲステロンとしての２１―置換プロゲステロン誘導体
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
AR040644A1 (es) * 2002-06-25 2005-04-13 Wyeth Corp Un moduladores del receptor de progesterona benzoxazina-2-tiona, una composicion farmaceutica, uso del compuesto para preparar un dedicamento para tratar una enfermedad neoplasica-hormona-dependiente y el uso de un compuesto benzoxazina-2-tiona, benzoxazina-2-ilideno cianamida o benzoxazina-2-iliden
US7638525B2 (en) * 2004-10-27 2009-12-29 Janssen Pharmaceutica N.V. Trisubstituted thiophenes as progesterone receptor modulators
WO2007103510A2 (fr) * 2006-03-08 2007-09-13 Danco Laboratories Llc Methodes, regimes posologiques et medicaments utilisant des agents antiprogestatifs dans le traitement de certains troubles
CA2753425A1 (fr) * 2009-02-24 2010-09-02 Medivation Prostate Therapeutics, Inc. Composes specifiques de type diarylhydantoine et diarylthiohydantoine

Also Published As

Publication number Publication date
EP2664325A1 (fr) 2013-11-20
AU2013261081A1 (en) 2014-12-04
TW201408306A (zh) 2014-03-01
JP2015516461A (ja) 2015-06-11
WO2013171684A1 (fr) 2013-11-21
CA2872233A1 (fr) 2013-11-21
MX2014013911A (es) 2015-01-12
US20150209373A1 (en) 2015-07-30
BR112014028629A2 (pt) 2018-04-24
KR20150013596A (ko) 2015-02-05
EA201491939A1 (ru) 2015-02-27
CN104411302A (zh) 2015-03-11
CO7151508A2 (es) 2014-12-29
EP2849734A1 (fr) 2015-03-25

Similar Documents

Publication Publication Date Title
IL269852B (en) Combined treatments and uses for the treatment of demyelination disorders
IL265774B (en) Diagnosis, prevention and treatment of joint diseases
HK1210599A1 (en) Abuse deterrent pharmaceutical compositions for controlled release
EP3180009A4 (fr) Formes galéniques d'acide zolédronique pour le traitement de la douleur
EP2890440A4 (fr) Dispositifs et procédés pour le traitement d'une maladie vasculaire
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
EP3068289A4 (fr) Prévention et traitement de sorties de lit, de chutes de lit et d'autres états
IL234413B (en) Liver x receptor modulators for the treatment of diseases and skin disorders
EP3038647A4 (fr) Polythérapie pour le traitement du glioblastome
EP2879617A4 (fr) Dispositifs et méthodes de traitement d'occlusion de l'artère ophtalmique
IL248130A0 (en) Isoindolinone compounds as gpr119 regulators in the treatment of diabetes, obesity, dyslipidemia and related diseases
EP3141603A4 (fr) Agent thérapeutique ciblant le gpc3 pour administration à des patients pour qui la thérapie par agent thérapeutique ciblant le gpc3 est efficace
EP3065768A4 (fr) Thérapie pour le traitement ou la prévention d'états associés au saignement ou à l'hypocoagulation
EP3038474A4 (fr) Combinaison nutraceutique pour la prévention et le traitement du diabète de type 2
EP2869819A4 (fr) Compositions, procédés et/ou dispositifs destinés à la prévention et/ou au traitement d'affections de type sécheresse oculaire
TN2017000498A1 (en) Positive allosteric modulators of muscarinic m2 receptor
HK1221656A1 (zh) σ受体配体在预防和治疗与间质性膀胱炎/膀胱疼痛综合征(IC/BPS)相关疼痛中的应用
ZA201408769B (en) Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent.
IL242355B (en) Cannabidiol for the prevention and treatment of graft-versus-host disease
EP3103446A4 (fr) Composition pharmaceutique destinée à la prévention et au traitement de la myopie pernicieuse
WO2013163562A3 (fr) Compositions et méthodes de traitement de l'espt et de maladies associées
HK1202813A1 (en) Progesterone receptor modulators for use in preventing or treating androgen mediated diseases
MX2016011706A (es) Formulaciones de progesterona.
WO2014056779A8 (fr) Médicament destiné à la prévention et au traitement d'une maladie neurodégénérative
EP2905021A4 (fr) Moyen pour la prévention et le traitement de troubles comportementaux, psychiques et cognitifs